As Americans as asked to pay a greater portion of their healthcare expenditures, new insurance design models are being implemented, such as value-based insurance design, to combat issues like nonadherence.
As the healthcare industry in the United States moves full-speed ahead with shifting from a fee-for-service environment to a value-based one, some tools will be especially helpful. Value-based insurance design (VBID) can be used to combat nonadherence as Americans are asked to pay a greater portion of their healthcare expenditures.
If you’re unfamiliar with the concept, here are 5 things to know about VBID:
1. The concept is 15 years old. The push for value-based care may just be gaining speed, but the concept of VBID was first introduced in 2001 by A. Mark Fendrick, MD, and Michael E. Chernew, PhD, before they became the co-editors-in-chief of The American Journal of Managed Care (AJMC). At the time, VBID was being called “benefit-based co-pay,” but the name was soon changed. The basic idea was that high-value services should cost less so they would be utilized more, and low-value services should cost more so they would be utilized less frequently.
2. VBID uses clinical nuance. Although more people are becoming familiar with the concept of VBID “clinical nuance” is still new. Clinical nuance recognizes that medical services differ in the benefit provided and that the benefit derived from a specific service can depend on the patient using it, as well as when and where the service is provided, explained Dr Fendrick, Jason Buxbaum, MHSA, and Jonas de Souza, MD, in a paper published in AJMC. Clinical nuance allows the healthcare industry to shift attention from how much we spend to how well we spend healthcare dollars. Payment models that are redesigned with the tenets of clinical nuance in mind are essential in the shift from volume to value, Dr Fendrick wrote in the Harvard Business Review in 2013.
3. VBID plans can improve adherence. Studies have supported the notion that setting patients’ cost-sharing amounts in relation to the value the treatment offers can reduce barriers that prevent patients from receiving or taking treatments as prescribed. In 2014, a study from Niteesh Choudhry MD, PhD, and colleagues, found that plans that were more generous, targeted high-risk patients, had wellness programs, did not have disease management programs, and made the benefit available only for medication ordered by mail improved adherence between 2 to 5 percentage points. A 2013 study reported that although VBID plans didn’t reduce overall medical spending, patients had a greater likelihood of filling prescriptions when health insurers offered financial incentives through a VBID plan.
4. Employers are seeing benefits to implementing VBID. Employers are using VBID to encourage use of and increase access to evidence-based health services. Pitney Bowes created and launched a VBID initiative in 2002, making it the first company to fully implement this approach. First the company reduced copayments for drugs that treat asthma, diabetes, and hypertension, then for statins. According to a study of the Pitney Bowes statin initiative, patient adherence to statins had stabilized with adherence 2.8% higher in the Pitney Bowes group compared with a control group immediately after the policy was implemented.
Companies like Caterpillar, Inc, Hannaford Brothers Company, and UnitedHealthcare have used a VBID approach to improve employee health, Dr Fendrick wrote in the report “Value-Based Insurance Design Landscape Digest,” which outlines how companies are using VBID to lower or eliminate financial barriers to high-value drugs or services.
5. Medicare Advantage is implementing a pilot.
In 2015, CMS announced that it would test whether providing Medicare Advantage organizations with the ability to integrate VBID would increase enrollee satisfaction, improve clinical outcomes, reduce plan expenditures, and save money for Medicare and beneficiaries. The model test is set to run 5 years in 7 states: Arizona, Indiana, Iowa, Massachusetts, Oregon, Pennsylvania, and Tennessee. This test is unique because existing regulations have prevented the incorporation of VBID in Medicare Advantage because these plans will not conform with the uniformity requirements.
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More